NeurOp’s technology to optimize selective and context-dependent NMDA inhibitors has led to the discovery of several proprietary compounds. Screening for drug-like properties among this group of compounds led to the identification of NP10679.
- Over 100-fold more potent at GluN2B-containing NMDA receptors than other subtypes
- 6-fold greater potency in lower pH – a context relevant to a number of CNS disorders
- Excellent drug-like properties, such as brain penetrance, half-life and oral bioavailability
After successful preclinical development, NP10679 is currently in Phase 1 clinical trials.